ESR1 and breast cancer: ERα36 is expressed in both ER-positive and ER-negative breast cancer; however, ERα36 expression is more abundant in ER-negative breast cancer that constitutes ~30% of all breast cancers diagnosed in women in the US and is generally a more aggressive cancer that, typically lacks wild-type ERα (ERα66)-positive cells [3].